
Ep. 88 Beyond First-Line Therapy: Treatment Strategies for Advanced Neuroendocrine Tumors with Dr. Mark Lewis
10/30/2026
0:00
1:02:20
Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On this episode of BackTable Tumor Board, Dr. Aman Chauhan, a medical oncologist at UCSF, interviews Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health in Salt Lake City, about treatment strategies for advanced neuroendocrine tumors beyond first-line therapy. They start with what progression on a somatostatin analog really means, how grade, Ki-67, primary site, and the pace of liver disease shape the next step, and why observation is sometimes the right call. Dr. Lewis explains how he sets expectations for PRRT after NETTER-1 and NETTER-2, including the small but real risk of secondary myelodysplasia and leukemia.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast is supported by
Exelixishttps://www.exelixis.com/
---
Timestamps
00:00 - Introduction02:22 - Progression on a Somatostatin Analog05:34 - Tumor Biology, Grade, and Observation12:51 - Somatostatin Analogs and Carcinoid Syndrome18:50 - PRRT After NETTER-1 and NETTER-225:56 - Chemotherapy Versus Targeted Therapy32:35 - The CABINET Trial and Cabozantinib38:39 - Dosing and Toxicity of Oral Therapy43:57 - Liver-Directed Therapy and Rebiopsy48:08 - Future Trials and Alpha Emitters50:47 - When to Stop Somatostatin Analogs54:27 - Practice-Changing Trials and Sequencing Lessons59:25 - Closing Remarks
---
More about this episode
The conversation then turns to systemic therapy: where capecitabine and temozolomide still fit, the trade-offs of earlier targeted agents, and the inclusive design of the CABINET trial of cabozantinib in pancreatic and extra-pancreatic NETs. Dr. Lewis describes why an oral therapy matters for rural patients who cannot easily reach a center that offers PRRT, and both doctors share how they dose oral therapy and watch for early toxicity. They close with when to rebiopsy a disease that is changing, alpha emitters on the horizon, when to stop a somatostatin analog, and the sequencing mistake Dr. Lewis most wants listeners to avoid: doing something because you can rather than because you should.
---
Resources
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (CABINET). N Engl J Med. 2025https://pubmed.ncbi.nlm.nih.gov/39282913/
FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET (March 2025)https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017https://pubmed.ncbi.nlm.nih.gov/28076709/
Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide in newly diagnosed, advanced grade 2-3, well-differentiated GEP-NETs (NETTER-2). Lancet. 2024https://pubmed.ncbi.nlm.nih.gov/38851203/
Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE). Lancet. 2026https://pubmed.ncbi.nlm.nih.gov/42392118/
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023https://pubmed.ncbi.nlm.nih.gov/36260828/
Everolimus for Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3). N Engl J Med. 2011https://pubmed.ncbi.nlm.nih.gov/21306238/
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011https://pubmed.ncbi.nlm.nih.gov/21306237/
Treatment of the Malignant Carcinoid Syndrome: Evaluation of a Long-Acting Somatostatin Analogue. N Engl J Med. 1986https://pubmed.ncbi.nlm.nih.gov/2427948/
Moertel CG. Karnofsky Memorial Lecture: An Odyssey in the Land of Small Tumors. J Clin Oncol. 1987https://pubmed.ncbi.nlm.nih.gov/2443618/
Lower or Standard Dose Regorafenib in Refractory Metastatic Colorectal Cancer (ReDOS, trial record)https://clinicaltrials.gov/study/NCT02368886
Dr. Aman Chauhan, UCSF Health physician profilehttps://www.ucsfhealth.org/providers/aman-chauhan
Dr. Mark Lewis, Intermountain Health physician profilehttps://doctors.intermountainhealth.org/provider/mark-a-lewis/2558622
---
BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
More episodes from "BackTable Tumor Board"



Don't miss an episode of “BackTable Tumor Board” and subscribe to it in the GetPodcast app.








